Tool
Tirzepatide Clinical Trial Finder
All calculations show inputs, formula, date and disclaimer
Filters the trials in our own study records by drug, population, duration and evidence status, linking each to its registry entry and publication where captured. It covers the 17 studies we hold rather than the whole literature, and it shows which fields are still uncaptured.
Every trial below is in our study records with its identifiers. Where a cell is blank we have not captured that field, and the row stays visible saying so rather than being quietly dropped.
| Trial | Drug | Population | Duration | Evidence |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide once weekly | Adults with obesity (BMI 30 or above), or overweight (BMI | 72 weeks | Verified Verified |
| SURMOUNT-3 | not verified | Adults with overweight or obesity who completed a 12-week | 72 weeks | Verified Verified |
| SURMOUNT-4 | not verified | Adults with obesity who completed an open-label tirzepatid | 88 weeks total, 36-week open-label lead-in then 52-week randomised withdrawal | Verified Verified |
| SURMOUNT-5 | Tirzepatide once weekly at maximum tolerated dose | Adults with obesity but without type 2 diabetes; BMI 30 or | 72 weeks | Verified Verified |
| SURMOUNT-OSA | Tirzepatide once weekly at maximum tolerated dose | Adults with moderate-to-severe obstructive sleep apnoea an | 52 weeks | Verified Verified |
| SUMMIT | Tirzepatide once weekly at maximum tolerated dose | Adults with heart failure with preserved ejection fraction | 52 weeks to the symptom endpoint, with event follow-up | Verified Verified |
| SURMOUNT-1, three-year prediabetes analysis | Tirzepatide once weekly | The 1,032 SURMOUNT-1 participants who had both obesity and | 176 weeks of treatment followed by a 17-week off-treatment period | Verified Verified |
| SURPASS-2 | not verified | not verified | 40 weeks | Verified Verified |
| Body-composition analyses | not verified | not verified | not verified | Pending Verification pending |
| Renal outcome analyses | not verified | not verified | not verified | Pending Verification pending |
| SYNERGY-NASH | not verified | not verified | not verified | Pending Verification pending |
| PCOS evidence base | not verified | not verified | not verified | Pending Verification pending |
| SURPASS-CVOT | not verified | not verified | Approximately 4.5 years | Verified Verified |
| SURPASS programme | not verified | not verified | not verified | Pending Verification pending |
| Retatrutide (TRIUMPH programme) | Retatrutide | Adults with obesity, or overweight with weight-related com | not verified | Provider-reported Provider-reported |
| ATTAIN-1 | Orforglipron | Adults with obesity, or overweight with weight-related com | 72 weeks | Provider-reported Provider-reported |
| OASIS 4 | Oral semaglutide 25 mg once daily | 307 adults with obesity (BMI 30 or above) or overweight (B | 64 weeks of treatment plus a 7-week off-treatment follow-up | Verified Verified |
| SYNERGY-NASH | Tirzepatide | Adults 18-80 with biopsy-confirmed MASH, stage F2 or F3 fi | 52 weeks | Verified Verified |
Flat-rate structures make dose escalation financially neutral. NexLife holds one price across every covered dose, from $186 a month. Its plan pages state the terms before intake.
How this works, and what it will not do
Everything runs in your browser. No health information is requested, no request leaves the page — which you can confirm in your browser's network inspector while using it.
This tool organises what you establish. It does not rank providers, recommend a medication, or suggest a dose. Those are clinical decisions for a licensed clinician who knows your history, and a tool implying otherwise would be doing something worse than being unhelpful.
Questions readers actually ask
Does this tool store my answers?
No. Everything runs in your browser and nothing is transmitted or saved.
Will it tell me which provider to use?
No. It organises what you establish and names what is still open. It does not rank or recommend.
Does it work without JavaScript?
The explanation and checklist are readable without it. The generated summary requires JavaScript.
Related on this site
- All toolsTools
- GLP-1 Total Cost CalculatorTools
- Tirzepatide Provider Comparison ToolTools
- Annual GLP-1 Cost CalculatorTools
- Provider ranking methodologyCore & Trust
- Download the pricing recordsData
- Editorial StandardsCore & Trust
- Tirzepatide, Lean Mass and Muscle LossResearch
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- Tirzepatide and Type 2 Diabetes PreventionResearch
GLP-1 Tirzepatide Review. “Tirzepatide Clinical Trial Finder.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/tools/clinical-trial-finder/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.